中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.019 seconds)

    Heterocyclic substituted indolinones
    12.
    发明授权
    Heterocyclic substituted indolinones 失效
    杂环取代的二氢吲哚酮

    公开(公告)号：US4870077A

    公开(公告)日：1989-09-26

    申请号：US94871

    申请日：1987-09-10

    Applicant: Wolfgang Von Der Saal ,  Walter-Gunar Friebe ,  Alfred Mertens ,  Bernd Muller-Beckmann ,  Lothar Kling

    Inventor： Wolfgang Von Der Saal ,  Walter-Gunar Friebe ,  Alfred Mertens ,  Bernd Muller-Beckmann ,  Lothar Kling

    IPC: A61K31/50 ,  A61K31/535 ,  A61K31/54 ,  A61P9/00 ,  C07D209/34 ,  C07D209/46 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04

    CPC classification number: C07D403/04 ,  C07D209/34 ,  C07D413/04 ,  C07D417/04

    Abstract: Heterocyclic substituted indolinones of the formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl or hydroxyalkyl radical, R.sub.2 is a carboxyl group or an alkoxy-carbonyl, hydroxyalkyl or alkylcarbonyloxyalkyl radical or R.sub.1 and R.sub.2, together with the carbon atom to which they are attached, form a lactone having 4, 5 or 6 ring atoms, A-B is --CH.sub.2 --CH(R.sub.3)--, --CH.dbd.CR.sub.3 --, --CH.sub.2 --NH--, --NH--CH.sub.2 --, --CH.sub.2 --O--, --O--CH.sub.2 --, --CH.sub.2 --S-- or --S--CH.sub.2 -- radical, R.sub.3 being a hydrogen atom or an alkyl or hydroxyalkyl radical, or A is a valency bond and B is a methylene radical ##STR2## or an imino group ##STR3## R.sub.4, R.sub.5, and R.sub.6 independently being hydrogen atoms or alkyl radicals wherein the alkyl groups independently contain 1 to 6 carbon atoms; as well as the tautomers thereof and the physiologically acceptable salt thereof and the physiologically acceptable salts thereof with inorganic and organic acids, are disclosed, such as, for instance, the compound 5-(2,3,4,5-tetrahydro-3-oxopyridazin-6-yl)-3-ethoxycarbonyl-3-methyl-1H-indol n-2-one. The compounds of the invention are useful in the treatment of heart and circulatory diseases, for example, by producing a positive inotropic action in a patient to whom the compounds are administered.

    Abstract translation: 式（I）的杂环取代的二氢吲哚酮：其中R 1是氢原子或烷基或羟烷基，R 2是羧基或烷氧羰基，羟基烷基或烷基羰基氧基烷基或R 1和R 2与碳 它们连接的原子形成具有4,5或6个环原子的内酯，AB是-CH 2 -CH（R 3） - ， - CH = CR 3 - ， - CH 2 -NH-，-NH-CH 2 - ， - CH 2 -O-，-O-CH 2 - ， - CH 2 -S-或-S-CH 2 - 基，R 3是氢原子或烷基或羟烷基，或A是价键，B是亚甲基。 或亚氨基基团R4，R5和R6独立地为氢原子或烷基，其中烷基独立地含有1至6个碳原子; 以及其与无机和有机酸的互变异构体及其生理上可接受的盐及其生理上可接受的盐，例如化合物5-（2,3,4,5-四氢-3- 氧基哒嗪-6-基）-3-乙氧基羰基-3-甲基-1H-吲哚-2-酮。 本发明的化合物可用于治疗心脏和循环系统疾病，例如通过在施用化合物的患者中产生正性肌力作用。

    Device for injection syringe
    13.
    发明授权
    Device for injection syringe 失效
    注射器装置

    公开(公告)号：US4373526A

    公开(公告)日：1983-02-15

    申请号：US253925

    申请日：1981-03-19

    Applicant: Lothar Kling

    Inventor： Lothar Kling

    IPC: A61M5/178 ,  A61M5/315 ,  A61M5/42 ,  A61M5/46 ,  A61M5/00

    CPC classification number: A61M5/46 ,  A61M5/422

    Abstract: Device for injection syringes for intramuscular and subcutaneous injections in human or veterinary medicine, characterized by an essentially tubular sleeve, whose inner diameter is slightly larger than the outer diameter of an associated injection syringe, and which is provided in the interior with at least one clamping-or holding element which releases, when a certain pressure is reached, the forward motion of the syringe body with the needle which is disposed in the sleeve. The length of the sleeve and the position of the clamping element in it are so dimensioned that the needle remains completely in the sleeve before the pressure is applied. After the application of the pressure, the desired depth of injection can be reached outside of the sleeve.

    Abstract translation: PCT No.PCT / DE80 / 00099 Sec。 371日期1981年3月19日 102（e）1981年3月19日PCT PCT 1980年8月8日PCT公布。 出版物WO81 / 日期：1981年2月5日。用于在人或兽医学中肌内和皮下注射的注射器的设备，其特征在于基本上为管状套筒，其内径略大于相关注射器的外径，并且其设置在 具有至少一个夹紧元件的内部，当达到一定压力时，释放注射器主体与设置在套筒中的针的向前运动。 套筒的长度和夹紧元件在其中的位置的尺寸被设计成使得针在施加压力之前针完全保持在套筒中。 在施加压力之后，可以在套筒外部达到所需的注射深度。

    Osteoblast-specific mitogens and drugs containing such compounds
    18.
    发明申请
    Osteoblast-specific mitogens and drugs containing such compounds 审中-公开
    成骨细胞特异性有丝分裂原和含有此类化合物的药物

    公开(公告)号：US20050014723A1

    公开(公告)日：2005-01-20

    申请号：US10893426

    申请日：2004-07-16

    Applicant: Angelika Esswein ,  Lothar Kling

    Inventor： Angelika Esswein ,  Lothar Kling

    IPC: C07F9/09 ,  A61K31/685 ,  A61K31/66

    CPC classification number: C07F9/091

    Abstract: Osteoblast-specific mitogens and drugs containing such compounds can be used for treating metabolic bone diseases. Novel compounds for this treatment include lysophosphatidylic acid derivatives selected from the group consisting of compounds of formula: wherein R1=alkenyl or alkynyl having from 6 to 24 carbon atoms; n=0-12; X=oxygen; the compounds (all-cis-5,8,11,14)-eicosatetraenoic acid 2-hydroxy-3-phosphonooxypropyl ester; cis-9, cis-12-octadecadienoic acid 2-hydroxy-3-phosphonooxypropyl ester; (all-cis-9,12,15)-octadecatrienoic acid 2-hydroxy-3-phosphonooxypropyl ester; cis-9-octadecenoic acid 2-hydroxy-3-phosphonooxypropyl ester; and erucic acid 2-hydroxy-3-phosphonooxypropylester being excluded, and the physiologically tolerable salts, esters, optically active forms, and racemates of said compounds.

    Abstract translation: 成骨细胞特异性有丝分裂原和含有此类化合物的药物可用于治疗代谢性骨病。 用于该处理的新型化合物包括选自下式的化合物的溶血磷脂酰衍生物：其中R 1 =具有6至24个碳原子的链烯基或炔基; n = 0-12; X =氧; 化合物（全顺式-5,8,11,14） - 二十碳四烯酸2-羟基-3-膦酰氧丙基酯; 顺式-9，顺式-12-十八碳二烯酸2-羟基-3-膦酰氧基丙基酯; （全顺式-9,12,15） - 十八碳三烯酸2-羟基-3-膦酰氧丙基酯; 顺-9-十八碳烯酸2-羟基-3-膦酰氧基丙酯; 和芥酸2-羟基-3-膦酰氧基丙基酯，以及所述化合物的生理上可耐受的盐，酯，旋光形式和外消旋体。

Patent Agency Ranking